Roccatello Dario, Fenoglio Roberta, De Simone Emanuele, Sciascia Savino
University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, ASL Città di Torino and University of Torino, 10154 Turin, Italy.
J Clin Med. 2025 Jan 2;14(1):208. doi: 10.3390/jcm14010208.
Recent progress has notably improved outcomes for patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), namely granulomatosis with polyangiitis and microscopic polyangiitis. Since 2021, several international scientific societies have recommended rituximab (RTX) as the preferred primary treatment for maintaining remission in AAV patients. Decisions regarding retreatment with RTX are based on individual patient risk factors for disease flare-ups and the potential consequences of such flares. In reviewing available evidence and reporting our experiences at G. Bosco Hub Hospital in Turin, Italy, we explore various trials focusing on the maintenance therapy in AAV and discuss areas of unmet need.
最近的进展显著改善了抗中性粒细胞胞浆抗体相关性血管炎（AAV）患者的治疗结果，即肉芽肿性多血管炎和显微镜下多血管炎。自2021年以来，几个国际科学协会推荐利妥昔单抗（RTX）作为AAV患者维持缓解的首选初始治疗药物。关于RTX再治疗的决策基于个体患者疾病复发的风险因素以及此类复发的潜在后果。在回顾现有证据并报告我们在意大利都灵的G. Bosco Hub医院的经验时，我们探讨了各种针对AAV维持治疗的试验，并讨论了未满足的需求领域。
